Foundation / Corporation
The Michael J. Fox Foundation (MJFF)
Grants to USA, Canada, and International university labs, for-profit companies, and nonprofit research institutions for research projects that will lead to new developments in treating Parkinson's disease. The funding source seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.
The Michael J. Fox Foundation (MJFF) funds research to better define, measure, and treat Parkinson’s disease as well as critical tools and other resources to advance that research. The purpose of this Request for Applications (RFA) is to fund target validation studies that leverage and translate basic research into new avenues for novel therapeutic development. We believe this will de-risk investments in therapeutic development, and accelerate the advancement of innovative therapies for PD patients.
The Target Advancement Program RFA seeks to build supporting evidence to rationalize biological targets and pathways for PD therapeutic development. Funding will support projects focused on validating novel targets and/or demonstrating links between existing targets and mechanisms believed to underlie PD neurodegeneration and/or dysfunction. Projects focused on validating novel targets relevant to motor and non-motor symptoms of PD may also be supported under this program. Priority will be given to proposals for novel targets that can already demonstrate a link to PD such as either a genetic association, an altered expression/function of the target in PD-relevant human tissue and/or clinical trial data implicating the target in PD. MJFF will prioritize applications utilizing experimental systems with high construct and predictive validity to human PD, such as patient-derived material and/or animal models utilizing clinically translatable endpoints.
Applications must focus on studies that achieve one or more of the following goals:
- Demonstrate altered expression, distribution or function of the target or its pathway in PD relevant human tissues and/or fluids.
- Provide evidence that modulation of the target or pathway specifically in vivo in whole mammalian PD models using genetic or pharmacological manipulations yields outcomes predictive of clinical efficacy.
- Elucidate target biology in human-relevant in vitro, cellular and in vivo models to understand physiological and pathological roles of the target as well as the potential for safety liabilities.
- Identify upstream or downstream signaling nodes of a validated target with therapeutic potential.
- Replicate or further validate published findings regarding a novel target.
- Develop an animal model or tool that can be used to further model or modulate PD-relevant targets.
- Demonstrate novel PD-relevant targets that could be translated into a biomarker (i.e., secreted or extracellularly expressed factors).
- Build clearer data validating the possible convergence of biological targets around established PD-relevant genetic and pathological pathways. Please note that MJFF has made significant investments in certain high-priority targets such as alpha-synuclein, LRRK2, GBA and Parkin/PINK1. Proposals to continue investigating in these areas will be considered against our existing portfolio.
Projects designed to assess emerging PD targets in pre-clinical models, human cellular models and human tissue and fluid matrices are eligible for this initiative. Applicants are encouraged to leverage existing resources if possible. Studies utilizing biosamples available through MJFF sponsored biospecimen collections (Access Data and Biospecimens program) or the Parkinson's Progressive Markers Initiative (PPMI) should not apply for funding through this initiative. Funding requests to support use of biosamples from these resources will be considered by the Foundation on a case-by-case basis.
GrantWatch ID#: 170931
Up to $150,000
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
Click here to apply online:
The Michael J. Fox Foundation for Parkinson's Research
Grand Central Station
P.O. Box 4777
New York, NY 10163-4777
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.